Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PARALLEL-GROUP DESIGN CLINICAL TRIAL OF THE EFFICACY AND TOLERABILITY OF CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg) pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (SERETIDE®) IN THE 12-WEEK TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA
Brief Summary: The aim of this study was to compare the efficacy and tolerability of the fixed combination beclomethasone/formoterol pMDI with that of fluticasone/salmeterol pMDI in patients with moderate to severe asthma


Options:
A: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Furoate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate Inhalation Powder, Other: Placebo Inhalation Powder 1 | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Propionate Inhalation Powder; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 1; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 2; Assigned to Arm(s): Fluticasone Furoate, Fluticasone Furoate/Vilanterol
B: Arm Label: Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg | Arm Label: Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg | Arm Label: Arm 3: Fluticasone Furoate 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate/ Vilanterol 200/25 mcg; Assigned to Arm(s): Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate/ Vilanterol 100/25 mcg; Assigned to Arm(s): Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100 mcg; Assigned to Arm(s): Arm 3: Fluticasone Furoate 100 mcg
C: Intervention Type: DRUG; Name: beclomethasone dipropionate plus formoterol fumarate combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate plus salmeterol xinafoate combination; Assigned to Arm(s): N/A
D: Arm Label: QVM149 150/50/80 μg; Type: EXPERIMENTAL; Interventions: Drug: QVM149 | Arm Label: QVM149 150/50/160 μg; Type: EXPERIMENTAL; Interventions: Drug: QVM149 | Arm Label: Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/fluticasone plus tiotropium | Intervention Type: DRUG; Name: QVM149; Assigned to Arm(s): QVM149 150/50/160 μg, QVM149 150/50/80 μg | Intervention Type: DRUG; Name: Salmeterol/fluticasone plus tiotropium; Assigned to Arm(s): Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg

Answer: C